Indoco Remedies Limited — Q1 FY26 earnings call

Call held 24 Jul 2025

Management summary

Indoco Remedies reported a mixed Q1 FY26 with consolidated revenue growth and improved EBITDA margins QoQ, driven by strong performance in OTC and semi-regulated markets. However, standalone revenues and international formulation business saw YoY declines, and the company continues to address the US FDA warning letter and manage increased interest costs. Management expressed confidence in quarter-on-quarter improvement and debt reduction plans.

Highlights

  • Consolidated net revenues increased 1.13% YoY to Rs. 429.1 crores and 11.77% QoQ.

  • Consolidated EBITDA margin improved to 4.1% in Q1 FY26 from negative in the preceding quarter.

  • OTC business showed significant growth of over 46% QoQ to Rs. 31.6 crores and achieved EBITDA break-even.

  • European authorities approved the plant for sterile product supply, opening new opportunities.

  • Domestic formulation business grew 1.3% YoY to Rs. 202.8 crores, with key therapeutic segments performing well.

Concerns

  • Standalone net revenues declined 2.64% YoY to Rs. 383.8 crores.

  • Standalone EBITDA margin significantly compressed to 3.9% from 13.1% in Q1 FY25.

  • International formulation business declined 11.33% YoY to Rs. 139.3 crores.

  • Ongoing remediation efforts for the US FDA warning letter on Goa Plant-2 continue to incur costs of ~Rs. 4 crores per quarter.

  • Interest costs increased, partly due to a Rs. 5.5-6 crores FX loss on mark-to-market.

Key financials

  1. Consolidated Net Revenues ₹429.1 Cr +1.1%YoY
  2. Standalone Net Revenues ₹383.8 Cr -2.6%YoY
  3. Consolidated EBITDA Margin 4.1%
  4. Standalone EBITDA Margin 3.9%
  5. Domestic Formulation Revenue ₹202.8 Cr +1.3%YoY
  6. International Formulation Revenue ₹139.3 Cr -11.3%YoY
  7. API Business Revenue ₹36.6 Cr +17.3%YoY
  8. OTC Revenue ₹31.6 Cr

What they filed

Q1 FY27: revenue up 6.4%, net profit up 280.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue433 411 390 440 485 +12%445 +8%476 +22%468 +6%
EBITDA40 12 -1 18 43 +8%32 +167%50 +5100%41 +128%
Net profit-10 -28 -41 -36 -9 +10%-29 −4%-24 +41%65 +281%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹236.1 Cr Total
  • Regulated Markets ₹95 Cr 40.2%
  • Europe Business ₹63.5 Cr 26.9%
  • Emerging Markets ₹44.3 Cr 18.8%
  • US Business ₹28.3 Cr 12.0%
  • AnaCipher CRO & Indoco Analytical Solutions ₹5 Cr 2.1%

Capital allocation

high confidence
  • Capex ₹50 Cr
    • Ongoing projects at Goa Plant-2
    • Ongoing projects at API site for Warren Remedies
    So I am not expecting anything more than around Rs. 50 Cr incrementally to be put in CAPEX this year.
  • Debt Gross ₹951 Cr
    • Repayment Reduced by Rs. 21 crore compared to March 25 ₹21 Cr
    • Repayment Planned repayment in the next 9 months ₹68 Cr
    debt level at this point of time, that is on 30th June, is overall at consolidation level, short term and long term put together is Rs. 951 crore, which is reduced by about Rs. 21 crore as compared to March 25.

Guidance & targets

Operations

  • Master Manufacturing Plan Full Operationalization Operations · by Q3 FY26 · High confidence All 4 plants up and going
    So by end of Q2 now, so come Q3, from day 1, we should have all plants up and going.

    — Aditi Panandikar

Regulatory

  • US FDA Goa Plant-2 Audit Invitation Regulatory · from September any time · High confidence Invite FDA for audit
    I think from September any time, we should be able to reach out to FDA to ask them to come and audit us.

    — Aditi Panandikar

  • US FDA Goa Plant-2 Warning Letter Resolution Regulatory · this calendar year · Medium confidence Resolution
    So like I said, we hope it would happen in this calendar year.

    — Aditi Panandikar

Revenue

  • US Sterile Product Supply Impact Revenue · from Q3 FY26 · High confidence Impact on revenue
    So I would say by Q3, Q3 is a good quarter in which we should be able to see some impact coming in from supply of sterile to US.

    — Aditi Panandikar

Profitability

  • EBITDA Margin Profitability · ongoing · High confidence Quarter-on-quarter improvement
    But save that, I can give you one commitment, you will see quarter-on-quarter improvement from here on.

    — Aditi Panandikar

R&D

  • Product Filings R&D · this year · High confidence 4-5 products
    So we expect to file 4-5 products this year.

    — Aditi Panandikar

  • R&D Spend as % of Revenue R&D · ongoing · High confidence 5%-5.5%
    But by and large, we keep it at 5%. I think we should be able to maintain that 5%-5.5%.

    — Aditi Panandikar

Costs

  • Remediation Cost Costs · ongoing · High confidence Rs. 4 crores per quarter
    Remediation continues. We continue to spend close to around Rs. 4 crores per quarter.

    — Aditi Panandikar

Capex

  • Incremental Capex Capex · FY26 · High confidence Rs. 50 crores
    So I am not expecting anything more than around Rs. 50 Cr incrementally to be put in CAPEX this year.

    — Aditi Panandikar

Debt

  • Debt Repayment Debt · next 9 months · High confidence Rs. 68 crores
    In remaining 9 months, we will be repaying about Rs. 68 crores as per our current plan.

    — Pramod Ghorpade

MR Productivity

  • Incremental PHY MR Productivity · by end of this year · Medium confidence 25,000 per man
    I am confident by end of this year, we should be able to add at least 25,000 per man by way of incremental PHY.

    — Aditi Panandikar

  • Low PHY Headquarters Improvement MR Productivity · ongoing · Medium confidence Reasonable level of at least 2
    Currently, the effort is to move the very low PHY headquarters to a reasonable level of at least 2, which should help us take the average much higher.

    — Aditi Panandikar

Capital Allocation

  • Warren Remedies Capital Infusion Capital Allocation · coming 3 quarters · High confidence Yes
    Yes. [in response to 'Are we going to infuse capital in Warren Remedies as it has a negative net worth of Rs. 52 crores to strengthen its balance sheet in coming 3 quarters?']

    — Aditi Panandikar

What to watch in Q2 FY26

US FDA Goa Plant-2 Audit Invitation & Inspection

next quarter (Q2 FY26)
Current Remediation efforts ongoing, audit invitation planned from September
Target FDA audit initiated or completed

Why it matters

Resolution of the warning letter is crucial for full operational capacity and US market revenue growth.

I think from September any time, we should be able to reach out to FDA to ask them to come and audit us.

Risks & concerns

  • US FDA Warning Letter on Goa Plant-2

    high

    Ongoing remediation efforts, with most expected to finish by August, and an audit invitation planned from September. Two out of four lines are already allowed to manufacture.

    Management acknowledged

  • Mark-to-Market Negative Impact

    medium

    Negative impact on Q1 FY26 numbers, contributing to overall challenges.

    Management acknowledged

  • Increased Interest Costs

    medium

    Finance cost includes Rs. 5.5-6 crores due to FX loss on mark-to-market, contributing to higher overall costs.

    Management acknowledged

  • Impact of Climate Change on Seasonal Products

    low

    Climate change impact directly affected the seasonal product portfolio in the domestic market, particularly Cital and Cyclopam.

    Management acknowledged

Q&A highlights

7 direct
US FDA Goa Plant-2 Remediation and Audit Timeline Direct
Our remediation efforts are on, they are almost near completion. We expect to finish most of it by August this year... from September any time, we should be able to reach out to FDA to ask them to come and audit us.

Provides a clear timeline for the resolution of the critical US FDA warning letter, a key overhang for the company.

Asked by Nirmam

Master Manufacturing Plan Rollout and Efficiency Direct
out of the 4 plants we talked about last time, 3 are now completely on... by end of Q2 now, so come Q3, from day 1, we should have all plants up and going.

Clarifies the progress and expected timeline for the full operationalization of the new manufacturing plan, which is crucial for efficiency and supply.

Asked by Nirmam

Domestic Market Growth and Performance Direct
if you look at the IQVIA analysis of 1st Quarter performance, then for the industry, Q1, for the covered market, there has been a growth of 8% and for Indoco Remedies, the growth is 10%.

Offers a third-party perspective (IQVIA) on the company's domestic market performance, indicating outperformance relative to the industry despite flat reported IRL revenue.

Asked by Nirmam

Interest Costs and Debt Reduction Direct
debt level at this point of time, that is on 30th June, is overall at consolidation level... is Rs. 951 crore, which is reduced by about Rs. 21 crore as compared to March 25... we expect another loan repayment in the coming period in 9 months, about Rs. 68 crores repayment.

Provides specific figures for current debt levels, recent reduction, and future repayment plans, addressing concerns about rising finance costs.

Asked by Nirmam

Capital Infusion in Warren Remedies and FPP Holdings Direct
Are we going to infuse capital in Warren Remedies because it has a Rs. 52 crore negative net worth to strengthen the balance sheet? [Aditi Panandikar: Yes.] And also in our US subsidiary, which has a negative net worth, in FPP Holdings? [Aditi Panandikar: No, in FPP, that is not required. So you are expecting it will become profitable? [Aditi Panandikar: Yes.]

Clarifies the company's strategy for supporting its subsidiaries, indicating a planned capital infusion for Warren Remedies and expected profitability for FPP Holdings.

Asked by Kenil Mehta

EBITDA Improvement Timeline Partial
it would be very tough at this stage to give any numbers... our first intent would be to get back to those levels [11%-13%] and I would wait for another quarter to give you some kind of a future path. But save that, I can give you one commitment, you will see quarter-on-quarter improvement from here on.

Management acknowledges the challenge of providing specific EBITDA targets but commits to sequential improvement, setting an expectation for future quarters.

Asked by Sudarshan Padmanabhan

R&D Expenses and Pipeline Direct
So we expect to file 4-5 products this year. And regarding the increased R&D expenditures, this is typically because in the 1st Quarter of the year, you see a lot of expense on R&Ds... But by and large, we keep it at 5%. I think we should be able to maintain that 5%-5.5%.

Outlines the product pipeline for the year and explains the rationale behind current R&D spend, providing insight into future growth drivers and cost management.

Asked by Rehan Saiyyed

US FDA Inspection for Remaining Lines and Revenue Ramp-up Direct
My question was, what is remaining for which they have to come and inspect and then approve it? For that particular line, when is the earliest you see that line coming back into production? [Aditi Panandikar: So like I said, we hope it would happen in this calendar year.]

Focuses on the timeline for full US FDA approval for all lines at Goa Plant-2, which is critical for maximizing US market potential and revenue ramp-up.

Asked by V. P. Rajesh

2 min read 6 chapters

Detailed narrative

Q1 FY26 Financial Performance Overview

Indoco Remedies reported consolidated net revenues of Rs. 429.1 crores for Q1 FY26, marking a 1.13% year-on-year growth and an 11.77% quarter-on-quarter increase. Standalone net revenues stood at Rs. 383.8 crores, reflecting a 2.64% YoY decline but a 12.52% QoQ growth. Consolidated EBITDA margin improved to 4.1% from a negative figure in Q4 FY25, while standalone EBITDA margin was 3.9%, up from 1% QoQ, despite a negative mark-to-market impact on numbers.

Regulatory & Operational Updates

The company received approval from European authorities for sterile product supply, which is expected to open new opportunities. Remediation efforts for the US FDA warning letter on Goa Plant-2 are nearing completion, with most work anticipated to finish by August 2025, and an audit invitation to the FDA planned from September. The master manufacturing program's Phase-1 rollout has seen 3 out of 4 plants fully operational, with the remaining plant expected to be fully operational by Q3 FY26.

Business Segment Performance

Domestic formulation business grew 1.3% YoY to Rs. 202.8 crores, with strong performance in therapeutic segments like Gastrointestinal, Anti-infective, Stomatology, and Respiratory. International formulation revenue, however, declined 11.33% YoY to Rs. 139.3 crores, primarily due to regulated markets (US at Rs. 28.3 crores, Europe at Rs. 63.5 crores). Emerging markets demonstrated robust growth, increasing from Rs. 29.8 crores to Rs. 44.3 crores. The API business revenue grew 17.31% YoY to Rs. 36.6 crores, and the OTC business achieved over 46% QoQ growth to Rs. 31.6 crores, reaching EBITDA break-even.

Cost Management & Profitability Outlook

Indoco Remedies is actively focusing on cost containment across its manufacturing sites and sales functions. Remediation costs related to the Goa Plant-2 continue at approximately Rs. 4 crores per quarter. Management aims to restore EBITDA margins to the 11-13% range seen in previous years and committed to achieving quarter-on-quarter improvement in profitability. Other expenses are being closely monitored, with an expectation that they will not increase proportionally with sales growth.

Capital Allocation & Debt Management

The company's total debt stood at Rs. 951 crores as of June 30, 2025, a reduction of Rs. 21 crores compared to March 2025. A further repayment of Rs. 68 crores is planned over the next 9 months. Incremental CAPEX for FY26 is projected to be around Rs. 50 crores, allocated to ongoing projects at Goa Plant-2 and the API site for Warren Remedies. Capital infusion is planned for Warren Remedies to address its negative net worth, while the US subsidiary FPP Holdings is expected to become profitable without additional capital.

R&D and Product Pipeline

Indoco Remedies plans to file 4-5 products this year, indicating a continued focus on pipeline development. R&D expenses, which were higher in Q1 due to sample purchases, are targeted to be maintained within the 5%-5.5% range of revenue. The company is also working on improving MR productivity, aiming to add at least 25,000 per man by way of incremental PHY by year-end and improve low-performing headquarters to a reasonable level of at least 2.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls